Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bouncing off of 50 day moving average, nice entry point for those who want to be long.JMHO
http://stockcharts.com/charts/gallery.html?s=aryc
Your right on point with that Bart
JMHO Looks like it building for a new run according to Intra day charts
http://www.windchart.com/stockta/analysis?symbol=ARYC&country=USA&cobrand=stockta
Record Volume !! Nice to see that ARYC can trade with some interest. It looks like the ship has a new propeller Admiral.Its about time they get there due. Someone sees something on the Horizon.
Silver what is wrong with exposing the real story to the street. JMHO There is nothing wrong with exposure.NASDAQ,AMEX and NYSE companies do it to. Pumping is only your interpretation.JMHO Again Independent reporting validates this is NOT a PUMP
http://www.genomeweb.com/search/google?cx=001523166877881412738:giguif19v6c&cof=FORID:11&query=Arrayit+corporation,+Sunnyvale,+CA&op=Search&as_q=more:recent4&form_build_id=form22b05a4a551801f1794f12961f8deae0&form_id=google_cse_searchbox_form
http://www.companiesandmarkets.com/Summary-Market-Report/point-of-care-diagnostics-2010-and-beyond-rapid-testing-at-a-crossroads-167009.asp
JMHO MANY CHANGES COULD HAVE OCCURRED SINCE 4 months ago Dec 31,2009 which is the information required by the 10K. JMHO It is still unclear as to percentages owned by this secret group as you refer to them.It may have been returned by non-performance or who knows. The John Howell issue is still at debate . JMHO Is it not fair to think all this connection to Houston and John Howell can easily be replaced with the Schenas controlling the BOD and over 51% of the shares outstanding? There is NO dirt on the Schenas. These guys are smart. JMHO
WoW Some real activity now beginning. Some interesting posts. All my DD points to real products real opportunities for big revenue growth. One thing I would point out is. If people want to distinguish between pump in reality all they need to do is follow independent analysis by the industry trade magazines and independent publishings some links listed below. ARYC IS REAL Do YOUR DD. Paid sponsorship does not indicate automatic pumping as some have eluded to. This is effective way to get your info to the masses and let the markets determine the validity.The Street is smart and will always know the real story before everyone else and place their bets accordingly, in the end the fundamentals and science win in the end as Silver indicates . I dis agree with Silvers opinion and side with Rene Schena and the companies position in this matter. My research on Wall Street Grand indicates the real companies they recommend run up huge and stick and they have discovered big winners. The fluff companies obviously pop and drop not fault of WSG. They just tell the story and let the markets decide. It appears that WSG are super hot right now and are credited with major undiscovered companies. JMHO I do not think Houston is behind this WSG hiring as silver indicates.He does not know nor do I, let the markets decide.JMHO This constant drumbeat about the former Houston connection is of no present and future relevance.JMHO the recent anemic volume in Feb,March it appears the company has made the right moves and must be planning something very big. The Schenas are no pumpers their is third party validation galore all over the place here are some listed below for those who are lazy,I will do some of your DD for you.
http://www.genomeweb.com/search/google?cx=001523166877881412738:giguif19v6c&cof=FORID:11&query=Arrayit+corporation,+Sunnyvale,+CA&op=Search&as_q=more:recent4&form_build_id=form22b05a4a551801f1794f12961f8deae0&form_id=google_cse_searchbox_form
Arrayit listed here in this link 27th in alphabetical order.
http://www.companiesandmarkets.com/Summary-Market-Report/point-of-care-diagnostics-2010-and-beyond-rapid-testing-at-a-crossroads-167009.asp
I will gladly answer your question. This ARYC opportunity is out there on the street for any one to do their DD and many people are posting to other boards. I have seen info posted on other boards with outrageous claims. Its not me. If you want to check my posts on Yahoo its simple. I do not post to competitors boards, these are others, I only posted once to SQNM board as I think we have similar business models and quite frankly IMHO opinion straight up ARYC has more platform installations than SQNM 3200 for ARYC and only 300+ for SQNM do your DD. IMHO ARYC diagnostic for Ovarian also is a much larger market than SQNM prenatal.ARYC has much larger growth opportunity than SQNM because of it multiple business lines that are proven and solidified by the customer base of ARYC . CAPITAL is the only difference which the company represents is something they will obtain. Capital = revenue growth and will quickly catch up with others IMHO. I do not have the time to post that way with goofy predictions and are useless!!Real investors can tell the difference. If you want to be fair? When you read my posts here, they are not hype they are right down the middle based on public information obtained by my DD. I post To other boards check them out RIMM, TSRA,WDC,STEC and others,. Good luck to your ambitions, fair is fair I can do the same as you. This company like you say will prove itself, IMHO.
That was well said. I guess that was all that needed to sum that up, and you get the rest of the company on the house. I don't think anyone here understands the potential of this company outside the ovarian test. It is crazy to think that the products on the website seem not to attract peoples attention. Its science. What can I say. Hard for most to understand and I cant really put my finger on it either, just looking at its industry peers and they are on fire. A crap shoot I guess. I think I will take my ball and go home. Shorts and sellers must have it right. JMHO No on second thought I think I will do some more DD.
The answer is very simple you have pointed it out yourself. No one has seen these agreements. I would guess they are performance based and if no performance or money exchanged for the equity then those stakes are probably null and void. I dont know just a guess. These are smart people they would not give away the farm for nothing. 17 years in business. (Bear with me now I am bored with my RIMM trade so I have have a Laugh this is a little) Here is a impersonation of a fictitious conversation. Rene Schena speaking :" gee these guys are really good guys and I like the Galleria shopping mall,Thanks for such a lovely time here in Houston" says to Sapaugh,Carr,Sonfield, and Howell and Mark Schena says "I really like steak I ate in Houston and the oil wells. That dinner was so good that Rene? " I think we should just give these guys whatever they ask for dont you think ", "Oh but of course Mark lets give away a big stake in our subs because they are just sooo nice."
Just a joke Ha Ha
My point is Management are Bay area Silicon Valley Alumni and are always competing, because they always run into their friends that just raised 100 million for something, they compete at a high level. They are no dummies and would not cut a bad deal after the first one without someone giving them something in return. But you go ahead and sell or be short I am taking the risk with this one. JMHO and a quik laugh even if it wasn't funny. No disrespect to Mark Scena and Rene Schena, I was just having some fun.
I still do not see your point. These guys own stock in a company with huge upside, probably dumb luck they have business addresses like anybody else. John Howell is the current Ceo of Arrayit Diagnostics so what! what a lucky guy , that does not mean he cant or wont be replaced or do a good job, I have checked this company out, they have real products real science and smart people at the top of Arrayit and everyone buys their products. John Howell could be the recipient of pure luck running that division and if he is not the right guy I am sure they find somebody else. These guys did not stay in business for 17 years for being stupid. Give management some credit. JMHO
JMHO But Every once in awhile the long shot comes in, its just the odds. This heavy bid support and now offer buying looks real good to me. hey I have been burned before and have learned from it. Sometimes there is a convergence of the right time , a hot stock market, a hot sector that sucks up every company in the sector. Even though they may have stubbed their toe with the wrong initial partner doesn't mean the big dogs wont gobble up the company , Just look at the science , the sector the long business history and business accolades from their industry peers. Worst case the Acquisition hungry companies and greedy bankers will buy this out just for the science and products and name recognition. Are you guys crazy Do your DD your standing in front of a train bearing down on you that cant be stopped no matter how hard anyone tries JMHO. I am no desperate long I reevaluate every time I get a new set of data points, I don't have all my eggs in one basket. I listen and look into what is posted on this board and I cant seem to make a case to get short this thing especially at. .80 Someone is sniffing around this bad boy and will take it out no matter who the partners are.JMHO back to trading my other positions man this market has been kind to me the last 6 mo I am taking some of my winnings and taking a chance. I mean look at VRML.05 to 35, Sorry I got to see this a a long play only.JMHO
You seem to be getting astray. Why not talk about the current management who is running the business. Lets hear about them. They are as clean as snow and have a Stellar reputation and in business 17 yrsas far as my research takes me, Mark Schena is credited with creating the technology and Rene Schena was named to INC 500.You can not through any stones at current management. The shell guys yea you got them. If you have been around this business long enough you know that the guys who put the deals together, the shell guys seem to always have some dirt on them, that is their profession they do it all day long and its bound to happen, in this case Sapaugh,Carr ,Atty Sonfield, that does not mean the company that receives the trading public vehicle are the same types they could have got duped as to the vehicle but that does not mean they will drive into the ditch.They are smart people they can get good counsel and clean up the vehicle and looks to be working on that. Once in a while the bad guys read the situation wrong and end up with the company coming in being much better than they ever expected and generally get shaken out and replaced as the company blossoms. It happens, I grant you it is rare but it does happen. this is a perfect case study. I do not see any of these people you have mentioned staying around much longer or being affiliated if what you say is true. If they dump their shares then the smart money will pick it up no problem obviously that is happening. I am long this stock and make no bones about it. The way you talk, your short. The market will ultimately make the decision,its much larger than You or I. you make your case, I make mine , as for yahoo go do your dd
I smell something burning in the Toaster. That would probably be Short Bread. Your posts seem a little frantic and desperate. We like that you are a sleuth. Are you certain you have thoroughly ran down every detail? That is what makes a market Including shorts and longs. They can equally get burned. Silver nothing personal if your short but I would take this recent volume indication as a real sign to cover. I like your in-depth look at the company it helps me work on my DD. I do look at your points and take them seriously.When I look all I see is all ACES. JMHO
Bullish Buy signal is confirmed by American Bulls. I do not blindly follow these tools but do use them with other charts and most importantly the fundamentals and volume indicators. It seems something is brewing, lets hope it is money. JMHO Capital in my opinion is the thing this company needs most to become a high flyer. I TOTALLY AGREE WITH MCMAC LETS KEEP THIS BOARD ABOUT ARRAYIT AND NOT PERSONAL ATTACKS. EVERYONE IS ENTITLED TO THEIR OWN OPINION BUT LETS KEEP THAT ABOUT THE COMPANY NOT PEOPLE.
Here is link
http://www.americanbulls.com/StockPage.asp?CompanyTicker=ARYC&MarketTicker=OTC&TYP=S
Nice buying flurry at the close. We have seemed to attract some interest in this company. The full potential of this company cant be a secret very much longer.JMHO The sellers must have lost patience waiting for news.If this runs next week I am sure there will be people sick that they sold.JMHO We even have after hours trades.
4th qtr revs for VRML are $0 its a $25 dollar stock. ARYC is a steal at these prices they have four times the potential as Vermillion. Its the technology and potential not the financials. The institutions are not stupid they drove VRML to 35 and invested 40 million. i think they come into ARYC as well JMHO Look at a chart of VRML
http://stockcharts.com/charts/gallery.html?VRML
Its very obvious to anyone who looks at the fundamental picture. It is a lack of capital. funding will cure all ails and revenues will rocket north.
The DOJI Bullish Harami Cross Pattern. I have used this many times and made money, but it is not always 100% reliable.Definite signs of life and looking to exit the doldrums.
http://www.americanbulls.com/StockPage.asp?CompanyTicker=ARYC&MarketTicker=OTC&TYP=S/tag]
Spring Loaded for the Spring season. This has been coiling for months. It look ready to spring higher and has had good buying support when pressured. JMHO
Best Micro-array platforms in the industry and a few key relationships and this could blow sky high. On the matter of the courts I hope the Gods are ready to release their judgement.Smart buying on your part could turn into a new vessel for the Admiral. Buy Low Sell high. JMHO
It is in the hands of the three judges that heard the final arguments. Your crystal ball is as good as mine. I feel that this low volume situation we have portends a potential explosive move. just a feeling nothing more. JMHO
You can go to the official OTCBB website otcbb.com Enter the Arrayit symbol (ARYC) in the left hand corner. when the quote box opens, you will see the filings tab on the top row.click on that and then you will see all the filings made by Arrayit. I believe this site also has a filings link.
This should clear up any questions. straight from 10K filed 1/31/10 page 23
ITEM 3. LEGAL PROCEEDINGS
Civil Action number 01-2226 between TeleChem International, Inc., Pediatrix Screening, Inc. and Pediatrix Screening LP went to jury trial in the United States District Court in the Western District of Pennsylvania in the summer of 2007. The jury awarded TeleChem $5 million in damages for Pediatrix's breach of contract, fraudulent misrepresentation, and punitive damages. The jury awarded Pediatrix $1,085,001 for TeleChem's breach of contract. Pediatrix appealed the jury's decision, and requested that the damages award to TeleChem be reduced. This appeal was denied. Pediatrix put $5 million in bond, and submitted an appeal to the Third Circuit Court of Appeals to request that the damages award to TeleChem be reduced. The second appeal was heard on December 15, 2009 by a panel of three judges in the Third Circuit Court of Appeals in Philadelphia, PA. The parties expect the Third Circuit Court's decision at any time. The parties understand that the Third Circuit Court’s decision is final.
I would not pass judgement yet. These stakes may have been put together and given only if certain performance or capital was delivered, I hope to see that is the case. I would only see that the Wayne State parts are clearly set in stone as they are part of the technology solution. I would guess the large percentages could come back to the company if these parties did not deliver what was promised.JMHO. we will certainly know soon. You certainly are very good at breaking down a 10K. That is good for the board to know. we will all stay tuned. I certainly will follow up with the company on your concern, I hope to get answers for us all. I am sure you will do the same.
Sellers will be sorry, prices a gift to those who understand the gigantic upside. I will keep 100% real. There is no doubt that there seems to relentless selling and even dumping. It is public record that there are large positions held by people that have an ability to pressure the stock. I am not on this board to pump the stock. Buyers after doing their own due diligence should be naturally pumped about buying once they understand the company. The only thing that this company lacks is capital. My best guess is after all the company has endured,it will be able to capitalize the huge growth curve in its industry. It has huge industry credibility and someone smart on the street will see what a diamond in the ruff it is and get behind it in a big way. Leaving the sellers and dumpers crying after being whip sawed to the upside. I know at times I question whether this is the real deal, but every time I dig I find more facts that keep me steady and resolute about my convictions about this company. It easy to get discouraged by what seems to be a never ending selling spree.This companies fundamental core business and first class science and new diagnostics opportunity will win the day.It just take one catalyst of capital to light this powder keg. Hopefully the long awaited $5 million dollar jury win will be the fuse. It is long overdue.That turns the tide and everyone will be jumping on this one and taking the ride of a lifetime. JMHO Good luck to all who have the courage to reap the rewards.
Good question to another huge revenue driver for ARYC. My understanding is the 1. The lawsuit which ARYC won ,this was the very reason for the lawsuit (the trade secrets) needed to be out of the way. This has happened except for the release of the award $5 million which that verdict on the amount is imminent from the third circuit fed court. This could happen literally any day now. 2. Obviously is tabled for shortage of capital to take to market.The company as per its filings is diligently working to address that.
The only thing that I see as inaccurate are the FDA approval any day now and The float is much larger than he realizes, but the overall assessment of the prospects of ARYC are definitely on cue.
BULLS EYE ACCURATE POSTING ON AFFX YAHOO CHAT BOARD. This guy has it right.
Posting below or go see on yahoo symbol AFFX
ARYC ($0.95) = AFFX killer in future. Affymetrix should buyout Arrayit (ARYC) now of face the same challenges that YHOO is facing from monster growth of GOOG. At one point YHOO could have acquired YHOO for just $3 bln but didn't and the rest we know it well. ARYC = baby AFFX, ISGR or VRML in making because if any of you remember VRML went up from $0.10 to $34 on FDA approval. ARYC could get FDA nod on its Ovarian Cancer test kit any day now. Its got tiny stock float of not even 2 mln shares.
From ARYC sec filing:
"Arrayit competes with large and small, public and private companies. The industry has been historically dominated by Affymetrix which achieved strong market penetration by being the first public company to commercialize and promote microarray applications. A more recent entry to the market, Illumina, has taken significant market share from Affymetrix. However, both competitors face mid to long term scientific and technological challenges because they are limited by what they can deposit onto a microarray--DNA. Arrayit's patented printing technology can deposit any kind of molecule into a microarray, including DNA, proteins, antibodies, diagnostic elements and other compounds. These next generation microarrays represent the largest growth opportunity in the industry. Arrayit has a long-term advantage in its unique line of personal and high throughput microarray printers, highest sensitivity microarray scanners, top quality consumables, patented diagnostic methods, collaborative corporate culture, and competitive pricing".
ARRAYIT Diagnostics Symbol:ARYC ($1) = MULTI BILLION DOLLAR Anti Ovarian Cancer - FDA approval of its Ova Dx test kit very likely any day now - ARYC ($0.95) = SUPER GOLDEN BUYING OPPOORTUNITY.
ARYC will be a $10+ stock someday because its current market capital is barely $3 mln whereas its last qtr growth in sales was nearly 50%. Compare its 650 products sold to over 10,000 pharma cos/labs in nearly 50 countries and company's valuation with competitors like
VRML ($135 mln co - no revenue growth)
AFFX ($550 mln co - 13% revenue growth)
LIFE ($9 bln co - 60% revenue growth)
ISRG ($13.65 bln co - 40% revenue growth)
ILMN ($4.5 bln co - 12% revenue growth)
SQNM ($500+ mln co - negative 20% sales decline)
Also read its soon to be launched Ovarian Cancer, Prostate Cancer, Parkinson's disease tets kit which could generate BILLIONS OF DOLLARS in sales in future, read the company's press release
http://finance.yahoo.com/news/Arrayit-Di...
http://finance.yahoo.com/news/Arrayit-Co...
Some of Arrayit's customers are top of the cream like USDA, Austrian Institute of Technology, US Center for Disease Control, John Hopkins Uni, Sandia National Labs, Stanford Univ.
Don't missout on ARYC - LOAD UP under $1 now and thank me later.
I had bought 700 ISRG at $93 and still hold it as long term investment as I love this company and sector. I made a lot of money in VRML buying under $1 and selling between $8 - $13
Don't missout on ARYC - it could rise 20 fold !! Investors load up on ARYC. AFFX management think about acquiring ARYC to enhance your products and keep the leadership in the industry.
I disagree, there is always the possibility of a stock staying range bound. But in this case, with the biotech indices hitting new highs everyday and companies in biotech being bought left and right anything can happen. What gives me comfort is that the hot area of the market in biotech is the sweet spot right now for Arrayit and its technology. Arrayits science has long standing respect in the industry and this will finally pay off with major alliances, cash infusions ,partnerships and product launches. For those long be patient, it will be rewarded. Arrayit could be the winner some morning when you wake up. Price could gap up to some crazy number with news no one is anticipating. Thats how hot this sector is and thats how solid the science is at Arrayit. JMHO
You and others are sure to be rewarded for being confident about what you own. you have done some good DD as well. Another stock to look at is VHGI.ob
Right on track again. The reason the company never had a IPO is for the very reason that we are talking about. No one wanted to take them public because of the LEGAL outcome. This is still Plaguing the company. The company saw fit and rather smartly reversed merged to become public taking the chance to now have access to capital, It looks to play out beautifully. Once this this legal issue is resolved everything will fall into place. It wont be a $1 anymore or on the bulletin board either, NASDAQ next and then NYSE. Looking at the filings the largest percentage of their debt 80% is legal fees from fighting this lawsuit.
You point out ARYC biggest weakness but here is the fix.
Link here
http://sec.gov/Archives/edgar/data/1084507/000105901609000137/0001059016-09-000137-index.htm
Page 21
PART II – OTHER INFORMATION
ITEM 1 - LEGAL PROCEEDINGS
Civil Action number 01-2226 between TeleChem International, Inc., Pediatrix Screening, Inc. and Pediatrix Screening LP went to jury trial in the United States District Court in the Western District of Pennsylvania in the summer of 2007. The jury awarded TeleChem $5 million in damages for Pediatrix's breach of contract, fraudulent misrepresentation, and punitive damages. The jury awarded Pediatrix $1,085,001 for TeleChem's breach of contract. Pediatrix appealed the jury's decision, and requested that the damages award to TeleChem be reduced. This appeal was denied. Pediatrix put $5 million in bond, and submitted an appeal to the Third Circuit Court of Appeals to request that the damages award to TeleChem be reduced. The parties await the Third Circuit Court's response.
Yes you are right with H1N1; it never became the big deal it was made out to be; but none the less its there if it pops up again.
No one can deny Arrayit has the single largest number of platforms installed worldwide; although revenue has been as high as 12 million in past years.(ACCORDING TO FIRST PUBLIC FILING) the platform race is not where huge revenues exist in future but I dare say it could.. The sleeping giant is the installed base is the biggest in the world and once scientist and pharma realize that huge biomarker discoveries are being made with Arrayit platforms combined with their H25K complete human genome chip. Arrayit revenues could explode through the sale of chips currently listed at $500 plus on their website.
You are certainly right about Parkinsons'; Prostate and others to follow. I am gambling on some major pharmas partnering soon.
The only thing holding back the company is capital, science is not the problem . The life science companies are infuego and I expect to hear of investment capital in Arrayit soon.(Just speculation) Eventually money hungry bankers will get to funding Arrayit.
I agree with Bart let them take it down there. Once the Settlement announcement from Jury award is announced this wont be anywhere near .80. All I can say is this good news if it does . that can only mean one thing. A financing is on its way and the funders want the price lower to get a better deal on discount to market. JMHO
Regardless of that, this will be positive news since they will be funded and take a half billion a year product to market which will be a fair trade for dilution. ALL bets are off When and if the Company gets the Total Jury award.
Link Here
Civil Action number 01-2226 between TeleChem International, Inc., Pediatrix Screening, Inc. and Pediatrix Screening LP went to jury trial in the United States District Court in the Western District of Pennsylvania in the summer of 2007. The jury awarded TeleChem $5 million in damages for Pediatrix's breach of contract, fraudulent misrepresentation, and punitive damages. The jury awarded Pediatrix $1,085,001 for TeleChem's breach of contract. Pediatrix appealed the jury's decision, and requested that the damages award to TeleChem be reduced. This appeal was denied. Pediatrix put $5 million in bond, and submitted an appeal to the Third Circuit Court of Appeals to request that the damages award to TeleChem be reduced. The parties await the Third Circuit Court's response.
Then they will be covering their short BIG TIME.
We will be the only smart money on this one. Obviously you are doing your homework. I have done exhaustive research into ARYC before I committed to it %100. JMHO I think that Arrayit will be the first U.S. Company to have a IVDMIA Approval with OVADX just speculation on my part for the following reasons.
1. Arrayit has the number 1. in the world installed Micro Array Platform in the world 3500 and counting.
2. AGENDIA BUYS FROM ARRAYIT
I will leave the rest open for thoughts
The First with FDA IVDMIA Clearance
MammaPrint is the first and only in vitro diagnostic multivariate index assay (IVDMIA) to be cleared by the FDA for breast cancer recurrence. Prior to its clearance, the FDA reviewed evidence that the test had been properly validated for its use.(1)
When MammaPrint was cleared in February of 2007, The Director of the Office of In Vitro Diagnostic Evaluation stated, “There have been rapid advances in microarrays and other pioneering diagnostics, and a corresponding increase in the use and impact of these complex devices. This has prompted FDA to take a closer look at the potential risks as well as the benefits associated with such tests when they are developed and used in laboratories. This test clearance takes into account the development of these innovative technologies and ensures public health by carefully evaluating their performance.”
An IVDMIA is a device that combines the values of multiple variables using an interpretative function (bioinformatics algorithm) to provide a single, patient specific result, that is intended for use in the diagnosis of disease and which provides a result whose derivation is non-transparent and for that reason cannot be independently derived or verified by the end user. MammaPrint is the only gene expression breast cancer test currently available in the United States that has met the FDA's strict IVDMIA criteria.
MammaPrint's FDA clearance confers confidence in its safety and effectiveness, ensuring that the peer reviewed, published studies used in its development, validation and IVDMIA clearance have been evaluated by the United States Food and Drug Administration. The FDA label indicates that as a diagnostic tool, MammaPrint has a 98.9% degree of accuracy in classifying patients as Low Risk or High Risk and technical reproducibility of 98.5%.
It is significant, based upon these stringent requirements, that MammaPrint remains today the only FDA-cleared IVDMIA test for Breast Cancer.
IVDMIA TESTs are being approved by FDA
AGENDIA.COM
Companion Diagnostic Development, FDA Clearance and Commercialization
Agendia seeks to work with a limited number of pharmaceutical oncology groups to expedite programs in companion diagnostics. We are seeking partners who recognize our unique strategic scientific foundation and experience in developing FDA-cleared In-vitro Diagnostic Multivariate Index Assays (IVDMIA) and their successful commercialization.
Would it be a Big STRETCH to imagine that ARRAYIT MIGHT WORK WITH A BIG PHARMA FOR ITS TEST???????????????????? I HAVE NOT HEARD ANYTHING BUT ITS A THOUGHT.
THERE HAS BEEN OVER 3.5 MILLION SHARES BOUGHT, SOMEONE BELIEVES THIS TEST GOES TO MARKET.
Those Doubting Thomas Types will be here and SHOULD BE that what makes a market. The case FOR BUYING ARYC.
Interesting ARTICLE
Approximately 5,500 women in the UK and 21,000 women in the USA are diagnosed with ovarian cancer each year. Worldwide, around 140,000 women die of ovarian cancer every year.
Tragically, the overall five year survival rate is only 46 per cent in most developed countries (it is lower for more advanced stages). However, according to the National Cancer Institute, if diagnosis is made early, before the tumor has spread, the five year survival rate is nearer 93 per cent. In 2009 scientists in the US said that current tests for diagnosing ovarian cancer are not good enough .
Cervical Cancer / HPV Vaccine News Even modern screening tests for ovarian cancer, which include a blood test for the CA 125 marker, combined with ultrasound, often result in unnecessary surgery and "..are failing to catch early signs of the disease..", a study at the University of Alabama at Birmingham Comprehensive Cancer Center revealed.
LINK TO THIS article
http://www.medicalnewstoday.com/articles/159675.php
Bart is doing some good research Pot of gold at the end of the rainbow. Read entire post. AGENDIA A PUBLIC COMPANY HAD THEIR IVD FDA APPROVED GO TO THEIR SITE. THESE TESTS ARE BEING APPROVED. ARYC HAS 15 YEARS WORKING WITH THE FDA. THEY WILL SHOCK WALL STREET SOON.
In a letter to the newly confirmed Secretary, the group noted that while accurate, reliable, and timely genetic testing offers enormous promise to help shape our healthcare system to meet the challenges of the 21st century, “poor quality testing can harm patients and waste scarce resources.” Physicians already are using genetic tests – currently available clinically for some 1,500 diseases or conditions – to diagnose disease, to predict an individual patient’s risk of future disease, and to guide decision making about further diagnostic procedures and choices among therapeutic options. “Advanced diagnostic testing is becoming the standard of care for many diseases,” the group told Sebelius.
link here http://www.dnapolicy.org/news.release.php?action=detail&pressrelease_id=131
Agendia Receives U.S. FDA Clearance For MammaPrint Breast Cancer Diagnostic Test
Article Date: 07 Feb 2007 - 0:00 PDT
Agendia announced today that the U.S. Food and Drug Administration (FDA) has cleared the company's MammaPrint(C) breast cancer diagnostic test. MammaPrint(R) is a gene expression profiling service to assess the risk of recurrence in breast cancer patients. MammaPrint(R) represents a U.S. regulatory milestone as the first In Vitro Diagnostic Multivariate Index Assay (IVDMIA) to acquire market clearance from the FDA, and is the agency's first step toward standardizing these multi-gene expression tests.
"Today's FDA clearance of MammaPrint(R) is a milestone for patient care and safety," said Dr. Bernhard Sixt, Chief Executive Officer at Agendia. "As the first test of its kind cleared by the FDA, this type of regulatory review benefits breast cancer patients and provides regulatory clarity to the medical community. At present, MammaPrint(R) is the first cleared IVDMIA which can be marketed in the US in compliance with these new FDA guidelines. We are exploring ways to make this product available in the US."
"We are pleased about today's FDA announcement as it signifies an important first step in standardizing IVDMIAs to ensure a safe and welcomed advancement in cancer diagnostics," said Diane Blum, MSW, Executive Director of CancerCare.
This week, the FDA will hold a public hearing to discuss draft guidance developed by the agency regarding IVDMIAs. The FDA intends to regulate multi- gene molecular diagnostics tests that meet specific criteria to ensure maximum safety and efficacy, as well as to ensure IVDMIA results can be easily interpreted by physicians.
About Agendia BV
Agendia, located in Amsterdam, the Netherlands, is a world leader in gene expression analysis-based diagnostics with three products on the market. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia maintains close ties with several leading European academic centers to develop state of the art diagnostic tests for cancer. Agendia also offers its expertise to pharmaceutical companies focusing on development of highly effective personalized drugs in the area of oncology.
More information about Agendia BV and MammaPrint is available at http://www.agendia.com
Agendia BV
http://www.agendia.com
The bottom line in my opinion , (you might have to catch up on reading past posts)
1.There is a big seller out there which is Cloud Capital, Houston Texas, They have a lot of shares and are obviously dumb enough or "very conservative after such a windfall and or are liquidating a portion of their 12.5 million shares. I can ascertain as you do that they or someone is selling. Cloud Cap is the obvious blatant seller or there is a monster short position. They must not be up to speed on all the new technology available to smart people. The number of shares that keep being sold with no price appreciation is a dead give away since no one person or group has the number of shares they do. It would be such a coincidence if it just so happened that hundreds of shareholders would always be willing to sell everyday when most shareholders from the past have been wiped down to 500,000 shares after the reverse split in March 2009.
Total share volume since March 2009 is as follows from OTCBB.COM
Mar 368,540
Apr 68,427
May 194,572
Jun 313,197
July 450,804
Aug 414,859
Sep 1,032,550
Oct 721,765
Nov 890,305
Dec 822,076
Jan 636,592
Feb 403,304
Total Volume
6,948,530
since a float of only 500k was available to new buyers in March of 2009 upon the reverse split. That original float available to the public has changed hands 13.8 times in 11 months. That would mean that each original shareholder after the reverse split has sold their shares at least once and then the market has flipped those shares back and forth 12 times. If that were the case and none of the 12.5 had been sold, we would have at least seen a 6 fold increase in the price and should be around $10 a share. This only shows that there has been persistant addition to float. My software speculates that according to data I entered above plus the high and low for each day. there has been an additional 3.5 million shares added to the float. So the only supply for tradable shares were the 2.7 issued to Cloud in March of 2009 and the additional 9.7 million just issued in dec 2009. that is all the dilution that can get into the float. Until volume increases dramatically to soak up that float, the price will stay unchanged.
The only thing that will change this is big news from the company and we all know this could be anytime now. so it is a gift if prices stay here. I just hope these idiots have not sold a share and someone is shorting against the box. If so a new unique rule that was put in place last year when shorting financial stocks can come into play making them cover before delivering their original position in the box. Its little known to most, even securities attorneys who have not kept up with the change. I hope this is the case because when the volume comes and they get their first call against the box. Big time short covering will ensue even though they have the shares,according to the rule the cover must come from the open market and cant be any that have been issued in any debt financing allowing for the protection of companies that did this and then had death spiral financings. I hope these guy have been doing what I just outlined because. BOOOM up goes the stock anyday now. JMHO